BACKGROUND. An effective, long-acting bronchodilator could benefit patients with asthma who have symptoms not controlled by antiinflammatory drugs. We compared a new long-acting, inhaled beta 2-adrenoceptor agonist, salmeterol, with a short-acting beta 2-agonist, albuterol, in the treatment of mild-to-moderate asthma. METHODS. We randomly assigned 234 patients (150 male and 84 female patients 12 to 73 years old) to one of three treatment groups: one group received 42 micrograms of salmeterol twice daily, one received 180 micrograms of albuterol four times daily, and one received placebo. Treatment was assigned in a double-blind fashion, and all patients could use supplemental inhaled albuterol as needed during the 12-week treatment period. RESULTS. Measurements of the forced expiratory volume in one second, performed hourly for 12 consecutive hours, showed that a single dose of salmeterol produced a greater mean area under the curve than two doses of albuterol taken 6 hours apart (6.3 vs. 4.9 liter.hr, P < 0.05). The difference was significant on day 1 and at week 4 of the study, but not at week 8 or 12. Salmeterol was also more effective than albuterol or placebo (with albuterol taken as needed) in increasing the morning peak expiratory flow rate: salmeterol induced a mean increase of 24 liters per minute over the pretreatment values, as compared with a decrease of 6 liters per minute with albuterol (P < 0.001) and an increase of 1 liter per minute with placebo (P = 0.002). The mean overall symptom score was improved most by salmeterol treatment (P < 0.05), with the number of days with symptoms and of nights with awakenings decreasing by 22 percent and 52 percent, respectively; there were no differences in results between albuterol treatment and placebo administration. We found no evidence of tolerance to the bronchodilating effects of salmeterol, and adverse reactions to all the treatments were infrequent and mild. CONCLUSIONS. For the management of mild-to-moderate asthma, salmeterol given twice daily is superior to albuterol given either four times daily or as needed.
Source Information
Colorado Allergy and Asthma Clinic, Aurora 80012.
This article has been cited by other articles:
Weiss, K. B.
(2008). Drug Safety and Salmeterol: The Controversy Continues. ANN INTERN MED
149: 56-57
[Full Text]
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., Pizzichini, E., Sullivan, S. D., Wenzel, S. E., Zar, H. J.
(2008). Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J
31: 143-178
[Abstract][Full Text]
Moore, R. H., Millman, E. E., Godines, V., Hanania, N. A., Tran, T. M., Peng, H., Dickey, B. F., Knoll, B. J., Clark, R. B.
(2007). Salmeterol Stimulation Dissociates beta2-Adrenergic Receptor Phosphorylation and Internalization. Am. J. Respir. Cell Mol. Bio.
36: 254-261
[Abstract][Full Text]
Rider, N. L., Craig, T. J.
(2006). A Safety Review of Long-Acting {beta}2-Agonists in Patients With Asthma. JAOA: Journal of the American Osteopathic Association
106: 562-567
[Abstract][Full Text]
Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F. Jr., Boushey, H. A., Deykin, A., Fahy, J. V., Sorkness, C. A., Chinchilli, V. M., Craig, T. J., DiMango, E., Kraft, M., Leone, F., Martin, R. J., Peters, S. P., Szefler, S. J., Liu, W., Israel, E., for the National Heart Lung and Blood Institute's,
(2006). beta-Adrenergic Receptor Polymorphisms and Response to Salmeterol. Am. J. Respir. Crit. Care Med.
173: 519-526
[Abstract][Full Text]
Peek, E. J., Richards, D. F., Faith, A., Lavender, P., Lee, T. H., Corrigan, C. J., Hawrylowicz, C. M.
(2005). Interleukin-10-Secreting "Regulatory" T Cells Induced by Glucocorticoids and {beta}2-Agonists. Am. J. Respir. Cell Mol. Bio.
33: 105-111
[Abstract][Full Text]
Chu, E. K., Drazen, J. M.
(2005). Asthma: One Hundred Years of Treatment and Onward. Am. J. Respir. Crit. Care Med.
171: 1202-1208
[Abstract][Full Text]
Sin, D. D., Man, J., Sharpe, H., Gan, W. Q., Man, S. F. P.
(2004). Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis. JAMA
292: 367-376
[Abstract][Full Text]
D'Alonzo, G. E. Jr.
(2004). Levalbuterol in the Treatment of Patients With Asthma and Chronic Obstructive Lung Disease. JAOA: Journal of the American Osteopathic Association
104: 288-293
[Abstract][Full Text]
Green, R H, Brightling, C E, Pavord, I D, Wardlaw, A J
(2003). Management of asthma in adults: current therapy and future directions. Postgrad. Med. J.
79: 259-267
[Abstract][Full Text]
Hanania, N. A., Sharafkhaneh, A., Barber, R., Dickey, B. F.
(2002). {beta}-Agonist Intrinsic Efficacy: Measurement and Clinical Significance. Am. J. Respir. Crit. Care Med.
165: 1353-1358
[Full Text]
Nightingale, J. A., Rogers, D. F., Barnes, P. J.
(2002). Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma*. Chest
121: 1401-1406
[Abstract][Full Text]
KIPS, J. C., PAUWELS, R. A.
(2001). Long-acting Inhaled beta 2-Agonist Therapy in Asthma. Am. J. Respir. Crit. Care Med.
164: 923-932
[Full Text]
Lazarus, S. C., Boushey, H. A., Fahy, J. V., Chinchilli, V. M., Lemanske, R. F. Jr, Sorkness, C. A., Kraft, M., Fish, J. E., Peters, S. P., Craig, T., Drazen, J. M., Ford, J. G., Israel, E., Martin, R. J., Mauger, E. A., Nachman, S. A., Spahn, J. D., Szefler, S. J., for the Asthma Clinical Research Network of the Na,
(2001). Long-Acting {beta}2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial. JAMA
285: 2583-2593
[Abstract][Full Text]
Lemanske, R. F. Jr, Sorkness, C. A., Mauger, E. A., Lazarus, S. C., Boushey, H. A., Fahy, J. V., Drazen, J. M., Chinchilli, V. M., Craig, T., Fish, J. E., Ford, J. G., Israel, E., Kraft, M., Martin, R. J., Nachman, S. A., Peters, S. P., Spahn, J. D., Szefler, S. J., for the Asthma Clinical Research Network of the Na,
(2001). Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial. JAMA
285: 2594-2603
[Abstract][Full Text]
Eccles, M., Rousseau, N., Higgins, B., Thomas, L.
(2001). Evidence-based guideline on the primary care management of asthma. Fam Pract
18: 223-229
[Full Text]
MOY, M. L., ISRAEL, E., WEISS, S. T., JUNIPER, E. F., DUBÉ, L., DRAZEN, J. M., the NHLBI Asthma Clinical Rese,
(2001). Clinical Predictors of Health-related Quality of Life Depend on Asthma Severity. Am. J. Respir. Crit. Care Med.
163: 924-929
[Abstract][Full Text]
D'Urzo, A. D., Chapman, K. R., Cartier, A., Hargreave, F. E., Fitzgerald, M., Tesarowski, D.
(2001). Effectiveness and Safety of Salmeterol in Nonspecialist Practice Settings. Chest
119: 714-719
[Abstract][Full Text]
Quarton, J.
(2001). On demand use of {beta}2-agonists led to better asthma control than regular use in moderate to severe asthma. Evid. Based Nurs.
4: 14-14
[Full Text]
Lim, S., Jatakanon, A., Gordon, D., Macdonald, C., Chung, K. F., Barnes, P. J
(2000). Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax
55: 837-841
[Abstract][Full Text]
Donohue, J. F.
(2000). The Expanding Role of Long-Acting {beta}-Agonists. Chest
118: 283-285
[Full Text]
Guhan, A R, Cooper, S, Oborne, J, Lewis, S, Bennett, J, Tattersfield, A E
(2000). Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax
55: 650-656
[Abstract][Full Text]
ISRAEL, E., DRAZEN, J. M., LIGGETT, S. B., BOUSHEY, H. A., CHERNIACK, R. M., CHINCHILLI, V. M., COOPER, D. M., FAHY, J. V., FISH, J. E., FORD, J. G., KRAFT, M., KUNSELMAN, S., LAZARUS, S. C., LEMANSKE, R. F. Jr., MARTIN, R. J., MCLEAN, D. E., PETERS, S. P., SILVERMAN, E. K., SORKNESS, C. A., SZEFLER, S. J., WEISS, S. T., YANDAVA, C. N.
(2000). The Effect of Polymorphisms of the beta 2-Adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma. Am. J. Respir. Crit. Care Med.
162: 75-80
[Abstract][Full Text]
Demirkan, K., Tolley, E., Mastin, T., Soberman, J., Burbeck, J., Self, T.
(2000). Salmeterol Administration by Metered-Dose Inhaler Alone vs Metered-Dose Inhaler Plus Valved Holding Chamber. Chest
117: 1314-1318
[Abstract][Full Text]
SHAPIRO, G., LUMRY, W., WOLFE, J., GIVEN, J., WHITE, M. V., WOODRING, A., BAITINGER, L., HOUSE, K., PRILLAMAN, B., SHAH, T.
(2000). Combined Salmeterol 50 {micro}g and Fluticasone Propionate 250 {micro}g in the Diskus Device for the Treatment of Asthma. Am. J. Respir. Crit. Care Med.
161: 527-534
[Abstract][Full Text]
Rosenthal, R. R., Busse, W. W., Kemp, J. P., Baker, J. W., Kalberg, C., Emmett, A., Rickard, K. A.
(1999). Effect of Long-term Salmeterol Therapy Compared With As-Needed Albuterol Use on Airway Hyperresponsiveness. Chest
116: 595-602
[Abstract][Full Text]
Milgrom, H., Taussig, L. M.
(1999). Keeping Children With Exercise-induced Asthma Active. Pediatrics
104
: e38-e38
[Abstract][Full Text]
Groeben, H., Emala, C.
(1999). Is {beta}-Adrenergic-Mediated Airway Relaxation of Salmeterol Antagonized by Its Solvent Xinafoic Acid?. Chest
115: 1678-1683
[Abstract][Full Text]
Ramsdell, J. W., Klinger, N. M., Ekholm, B. P., Colice, G. L.
(1999). Safety of Long-term Treatment With HFA Albuterol. Chest
115: 945-951
[Abstract][Full Text]
Chervinsky, P., Goldberg, P., Galant, S., Wang, Y., Arledge, T., Welch, M. B., Stahl, E.
(1999). Long-term Cardiovascular Safety of Salmeterol Powder Pharmacotherapy in Adolescent and Adult Patients With Chronic Persistent Asthma: A Randomized Clinical Trial. Chest
115: 642-648
[Abstract][Full Text]
Lockey, R. F., DuBuske, L. M., Friedman, B., Petrocella, V., Cox, F., Rickard, K.
(1999). Nocturnal Asthma: Effect of Salmeterol on Quality of Life and Clinical Outcomes. Chest
115: 666-673
[Abstract][Full Text]
Teschemacher, A., Lemoine, H.
(1999). Kinetic Analysis of Drug-Receptor Interactions of Long-Acting beta 2 Sympathomimetics in Isolated Receptor Membranes: Evidence against Prolonged Effects of Salmeterol and Formoterol on Receptor-Coupled Adenylyl Cyclase. J. Pharmacol. Exp. Ther.
288: 1084-1092
[Abstract][Full Text]
van Noord, J A, Schreurs, A J M, Mol, S J M, Mulder, P G H
(1999). Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax
54: 207-212
[Abstract][Full Text]
Nelson, H., Kemp, J. P., Bieler, S., Vaughan, L. M., Hill, M. R.
(1999). Comparative Efficacy and Safety of Albuterol Sulfate Spiros Inhaler and Albuterol Metered-Dose Inhaler in Asthma. Chest
115: 329-335
[Abstract][Full Text]
Harrison, T W, Oborne, J, Wilding, P J, Tattersfield, A E
(1999). Randomised placebo controlled trial of beta agonist dose reduction in asthma. Thorax
54: 98-102
[Abstract][Full Text]
ANDREW MCIVOR, R., PIZZICHINI, E., TURNER, M. O., HUSSACK, P., HARGREAVE, F. E., SEARS, M. R.
(1998). Potential Masking Effects of Salmeterol on Airway Inflammation in Asthma. Am. J. Respir. Crit. Care Med.
158: 924-930
[Abstract][Full Text]
Taylor, D R., Town, G I., Herbison, G P., Boothman-Burrell, D., Flannery, E. M, Hancox, B., Harré, E., Laubscher, K., Linscott, V., Ramsay, C. M, Richards, G.
(1998). Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax
53: 744-752
[Abstract][Full Text]
Fabbri, L., Beghé, B., Caramori, G., Papi, A., Saetta, M.
(1998). Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax
53: 803-808
[Full Text]
Nelson, J. A., Strauss, L., Skowronski, M., Ciufo, R., Novak, R., McFadden, E.R.
(1998). Effect of Long-Term Salmeterol Treatment on Exercise-Induced Asthma. NEJM
339: 141-146
[Abstract][Full Text]
Pauwels, R. A., Lofdahl, C.-G., Postma, D. S., Tattersfield, A. E., O'Byrne, P., Barnes, P. J., Ullman, A., The Formoterol and Corticosteroids Establishing Th,
(1997). Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. NEJM
337: 1405-1411
[Abstract][Full Text]
WEERSINK, E. J. M., van ZOMEREN, E. H., KOETER, G. H., POSTMA, D. S.
(1997). Treatment of Nocturnal Airway Obstruction Improves Daytime Cognitive Performance in Asthmatics. Am. J. Respir. Crit. Care Med.
156: 1144-1150
[Abstract][Full Text]
LEMANSKE, R. F. JR., ALLEN, D. B.
(1997). Choosing a Long-term Controller Medication in Childhood Asthma . The Proverbial Two-edged Sword. Am. J. Respir. Crit. Care Med.
156: 685-687
[Full Text]
Wilding, P., Clark, M., Coon, J. T., Lewis, S., Rushton, L., Bennett, J., Oborne, J., Cooper, S., Tattersfield, A. E
(1997). Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ
314: 1441-1441
[Abstract][Full Text]
Green, S. A., Spasoff, A. P., Coleman, R. A., Johnson, M., Liggett, S. B.
(1996). Sustained Activation of a G Protein-coupled Receptor via ``Anchored'' Agonist Binding. MOLECULAR LOCALIZATION OF THE SALMETEROL EXOSITE WITHIN THE beta 2-ADRENERGIC RECEPTOR. J. Biol. Chem.
271: 24029-24035
[Abstract][Full Text]
Drazen, J. M., Israel, E., Boushey, H. A., Chinchilli, V. M., Fahy, J. V., Fish, J. E., Lazarus, S. C., Lemanske, R. F., Martin, R. J., Peters, S. P., Sorkness, C., Szefler, S. J., The National Heart Lung andBlood Institute's Asthm,
(1996). Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma. NEJM
335: 841-847
[Abstract][Full Text]
,
(1996). North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of asthma in adults. BMJ
312: 762-766
[Full Text]
Nelson, H. S.
(1995). {beta}-Adrenergic Bronchodilators. NEJM
333: 499-507
[Full Text]
Fuller, R W
(1994). Controversies in Management: Adverse effects are not proved. BMJ
309: 795-796
[Full Text]
Previous
